AbbVie Inc
ABBV: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$229.00 | Gpy | Xdshlhh |
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
We are holding steady to our fair value estimate for AbbVie following largely in-line first-quarter results. AbbVie continues to execute very well around the US Humira loss of exclusivity, which was a key factor in our moat rating increase to wide earlier in the year.